MovDisordV3, PascalFrancis, Corpus, bibRecord, 001963

Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial

Identifieur interne : 001963 ( PascalFrancis/Corpus ); précédent : 001962; suivant : 001964

Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial

Auteurs : Jacques Montplaisir ; Jeff Karrasch ; Jean Haan ; Dieter Volc

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0538579

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Impatience membre inférieur syndrome, Ropinirole, Long terme, Conduite à tenir, Essai clinique.

English descriptors

KwdEn :
- Clinical management, Clinical trial, Long term, Nervous system diseases, Restless legs syndrome, Ropinirole.

Abstract

The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial`
A11	`01`	`1`		`@1 MONTPLAISIR (Jacques)`
A11	`02`	`1`		`@1 KARRASCH (Jeff)`
A11	`03`	`1`		`@1 HAAN (Jean)`
A11	`04`	`1`		`@1 VOLC (Dieter)`
A14	`01`			`@1 Hôpital du Salcré-Coeur de Montréal @2 Montréal, Quebec @3 CAN @Z 1 aut.`
A14	`02`			`@1 Peninsula Clinical Research Centre @2 Kipparing, Queensland @3 AUS @Z 2 aut.`
A14	`03`			`@1 Neurologische Klinik, Schlafmedizinisches Zentrum @2 Moenchengladbach @3 DEU @Z 3 aut.`
A14	`04`			`@1 Confraternitaet -Privatklinik @2 Josefstadt, Wien @3 AUT @Z 4 aut.`
A20				`@1 1627-1635`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000158877800090`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 06-0538579`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02Q`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Impatience membre inférieur syndrome @5 02`
C03	`02`	`X`	`ENG`	`@0 Restless legs syndrome @5 02`
C03	`02`	`X`	`SPA`	`@0 Acroparestesia nocturna @5 02`
C03	`03`	`X`	`FRE`	`@0 Ropinirole @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Ropinirole @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Ropinirol @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Long terme @5 10`
C03	`04`	`X`	`ENG`	`@0 Long term @5 10`
C03	`04`	`X`	`SPA`	`@0 Largo plazo @5 10`
C03	`05`	`X`	`FRE`	`@0 Conduite à tenir @5 11`
C03	`05`	`X`	`ENG`	`@0 Clinical management @5 11`
C03	`05`	`X`	`SPA`	`@0 Actitud médica @5 11`
C03	`06`	`X`	`FRE`	`@0 Essai clinique @5 12`
C03	`06`	`X`	`ENG`	`@0 Clinical trial @5 12`
C03	`06`	`X`	`SPA`	`@0 Ensayo clínico @5 12`
C07	`01`	`X`	`FRE`	`@0 Trouble neurologique @5 37`
C07	`01`	`X`	`ENG`	`@0 Neurological disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Trastorno neurológico @5 37`
C07	`02`	`X`	`FRE`	`@0 Trouble sensibilité @5 38`
C07	`02`	`X`	`ENG`	`@0 Sensitivity disorder @5 38`
C07	`02`	`X`	`SPA`	`@0 Trastorno sensibilidad @5 38`
N21				`@1 353`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0538579 INIST
ET :	Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial
AU :	MONTPLAISIR (Jacques); KARRASCH (Jeff); HAAN (Jean); VOLC (Dieter)
AF :	Hôpital du Salcré-Coeur de Montréal/Montréal, Quebec/Canada (1 aut.); Peninsula Clinical Research Centre/Kipparing, Queensland/Australie (2 aut.); Neurologische Klinik, Schlafmedizinisches Zentrum/Moenchengladbach/Allemagne (3 aut.); Confraternitaet -Privatklinik/Josefstadt, Wien/Autriche (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 10; Pp. 1627-1635; Bibl. 22 ref.
LA :	Anglais
EA :	The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.
CC :	002B17; 002B02Q; 002B17F
FD :	Système nerveux pathologie; Impatience membre inférieur syndrome; Ropinirole; Long terme; Conduite à tenir; Essai clinique
FG :	Trouble neurologique; Trouble sensibilité
ED :	Nervous system diseases; Restless legs syndrome; Ropinirole; Long term; Clinical management; Clinical trial
EG :	Neurological disorder; Sensitivity disorder
SD :	Sistema nervioso patología; Acroparestesia nocturna; Ropinirol; Largo plazo; Actitud médica; Ensayo clínico
LO :	INIST-20953.354000158877800090
ID :	06-0538579

Links to Exploration step

Pascal:06-0538579

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation><inist:fA14 i1="01"><s1>Hôpital du Salcré-Coeur de Montréal</s1>
<s2>Montréal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
<affiliation><inist:fA14 i1="02"><s1>Peninsula Clinical Research Centre</s1>
<s2>Kipparing, Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
<affiliation><inist:fA14 i1="03"><s1>Neurologische Klinik, Schlafmedizinisches Zentrum</s1>
<s2>Moenchengladbach</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
<affiliation><inist:fA14 i1="04"><s1>Confraternitaet -Privatklinik</s1>
<s2>Josefstadt, Wien</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0538579</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0538579 INIST</idno>
<idno type="RBID">Pascal:06-0538579</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001963</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation><inist:fA14 i1="01"><s1>Hôpital du Salcré-Coeur de Montréal</s1>
<s2>Montréal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
<affiliation><inist:fA14 i1="02"><s1>Peninsula Clinical Research Centre</s1>
<s2>Kipparing, Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
<affiliation><inist:fA14 i1="03"><s1>Neurologische Klinik, Schlafmedizinisches Zentrum</s1>
<s2>Moenchengladbach</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
<affiliation><inist:fA14 i1="04"><s1>Confraternitaet -Privatklinik</s1>
<s2>Josefstadt, Wien</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical management</term>
<term>Clinical trial</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Restless legs syndrome</term>
<term>Ropinirole</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Impatience membre inférieur syndrome</term>
<term>Ropinirole</term>
<term>Long terme</term>
<term>Conduite à tenir</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MONTPLAISIR (Jacques)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KARRASCH (Jeff)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HAAN (Jean)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VOLC (Dieter)</s1>
</fA11>
<fA14 i1="01"><s1>Hôpital du Salcré-Coeur de Montréal</s1>
<s2>Montréal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Peninsula Clinical Research Centre</s1>
<s2>Kipparing, Queensland</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Neurologische Klinik, Schlafmedizinisches Zentrum</s1>
<s2>Moenchengladbach</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Confraternitaet -Privatklinik</s1>
<s2>Josefstadt, Wien</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1627-1635</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000158877800090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0538579</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02Q</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Impatience membre inférieur syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Restless legs syndrome</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Acroparestesia nocturna</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Long terme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Long term</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Conduite à tenir</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Clinical management</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Actitud médica</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble sensibilité</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Sensitivity disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno sensibilidad</s0>
<s5>38</s5>
</fC07>
<fN21><s1>353</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0538579 INIST</NO>
<ET>Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial</ET>
<AU>MONTPLAISIR (Jacques); KARRASCH (Jeff); HAAN (Jean); VOLC (Dieter)</AU>
<AF>Hôpital du Salcré-Coeur de Montréal/Montréal, Quebec/Canada (1 aut.); Peninsula Clinical Research Centre/Kipparing, Queensland/Australie (2 aut.); Neurologische Klinik, Schlafmedizinisches Zentrum/Moenchengladbach/Allemagne (3 aut.); Confraternitaet -Privatklinik/Josefstadt, Wien/Autriche (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 10; Pp. 1627-1635; Bibl. 22 ref.</SO>
<LA>Anglais</LA>
<EA>The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.</EA>
<CC>002B17; 002B02Q; 002B17F</CC>
<FD>Système nerveux pathologie; Impatience membre inférieur syndrome; Ropinirole; Long terme; Conduite à tenir; Essai clinique</FD>
<FG>Trouble neurologique; Trouble sensibilité</FG>
<ED>Nervous system diseases; Restless legs syndrome; Ropinirole; Long term; Clinical management; Clinical trial</ED>
<EG>Neurological disorder; Sensitivity disorder</EG>
<SD>Sistema nervioso patología; Acroparestesia nocturna; Ropinirol; Largo plazo; Actitud médica; Ensayo clínico</SD>
<LO>INIST-20953.354000158877800090</LO>
<ID>06-0538579</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001963 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001963 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0538579
   |texte=   Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial

Ropinirole is effective in the long-term management of restless legs syndrome : A randomized controlled trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri